A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Clin Cancer Res
; 29(22): 4555-4563, 2023 11 14.
Article
in En
| MEDLINE
| ID: mdl-37643133
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Adenoid Cystic
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article